11.0 Appendix 1

|  |  |  |
| --- | --- | --- |
| ***Company:*** | **Drug Shortage Risk Register***(Template as part of TR-68 (Revised), ©2024 PDA, Inc.)* | ***Date:*** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **ID** | **Product and Strength** | **Potential Drug Shortage Hazard** | **Hazardous Situations** | **Countries/ Regions Could be Affected** | **Affected Internal Area** | **Initial Risk Level** | **Risk Indicators** | **Planned Risk Control Actions** | **Rick Level After Risk Control** | **Person(s) Responsible** | **Status** | **Date Due** |
| *Unique reference number* | *Identify product and strength* | *Risk description in a newspaper headline style; reference as applicable* | *Root cause or risk assessment title* | *Identify countries/ regions that could be affected* | *All sites/locations, affiliates, and functional areas affected by a shortage* | *Risk Level or indication of the risk as high or medium. Note: Based on a consideration**of current shortage prevention controls and**their likely effectiveness* | *Potential leading and lagging indicators for this drug shortage risk* | *Planned mitigation actions, (CAPA number, if applicable)* | *Risk Level after mitigation or whether residual risk is high or medium* | *Who is responsible for coordination of the mitigation action(s)* | *“Planned,” “In process,” “Delayed,” or “Completed”* | *Current deadline forcompleting**recommended actions [dd.mm.yy]* |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |

**43** © 2024 Parenteral Drug Association, Inc. Technical Report No. 68 (Revised 2024)